The Peter MacCallum Neuroendocrine Unit Centre of Excellence organising committee invites you to attend the 5th Neuroendocrine Tumour Preceptorship on Friday 13th and Saturday 14th June 2025.

The Peter MacCallum Cancer Centre is Australia’s only public hospital solely dedicated to cancer treatment, research and education. The Neuroendocrine Tumour Unit at the Peter MacCallum, the largest in Australia, comprises of specialists from multiple disciplines, highly dedicated to the individualized management of patients with neuroendocrine tumour by leading edge clinical and laboratory research. The Unit has a statewide, regional and international referral base, consulting on over 150 new patients per year and was the first NET centre outside of Europe to be certified as a Centre of Excellence by the European Neuroendocrine Tumour Society (ENETS).

The 2025 NET Preceptorship will occur over one and half days at the Peter MacCallum Cancer Center in Melbourne. It will comprise of clinical problem-based lectures from relevant specialists on all aspects of the individualized multidisciplinary management of neuroendocrine tumours: from diagnosis, imaging, surgery, and medical therapy (medical oncology, endocrinology, nuclear medicine) and nursing. This will be based on our Unit’s extensive experience and treatment guidelines.

The meeting content is purely under the direct control of the Peter MacCallum Neuroendocrine Unit. The aims of the meeting are to emphasize the current standards, and common dilemmas, of management for patients with neuroendocrine tumours. It will focus on their considerable heterogeneity in terms of tumour biology of these tumours. The meeting will also emphasize the need for an individualized treatment approach based on disease biology and disease extent and the requirement for a multidisciplinary management plan. The meeting in this regard thus clearly provides the attending clinicians the practical knowledge base of neuroendocrine tumour management hence leading to the increased patient benefit. In addition to the quality of use of currently available therapeutic agents in this disease.